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Abstract
Early diagnosis improves melanoma survival, yet the histopathological diagnosis of cutaneous 
primary melanoma can be challenging even for expert dermatopathologists. Analysis of epigenetic 
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alterations, such as DNA methylation, that occur in melanoma can aid in its early diagnosis. Using 
a genome-wide methylation screen, we assessed CpG methylation in a diverse set of 89 primary 
invasive melanomas, 73 nevi, and 41 melanocytic proliferations of uncertain malignant potential, 
classified based on interobserver review by dermatopathologists. Melanomas and nevi were split 
into training and validation sets. Predictive modeling in the training set using ElasticNet identified 
a 40-CpG classifier distinguishing 60 melanomas from 48 nevi. High diagnostic accuracy (area 
under the receiver operator characteristics (ROC) curve (AUC)=0.996, sensitivity=96.6%, and 
specificity=100.0%) was independently confirmed in the validation set (29 melanomas, 25 nevi) 
and other published sample sets. The 40-CpG melanoma classifier included homeobox 
transcription factors and genes with roles in stem cell pluripotency or the nervous system. 
Application of the 40-CpG melanoma classifier to the diagnostically uncertain samples assigned 
melanoma or nevus status, potentially offering a diagnostic tool to assist dermatopathologists. In 
summary, the robust, accurate 40-CpG melanoma classifier offers a promising assay for improving 
primary melanoma diagnosis.
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INTRODUCTION
Cutaneous melanoma is an aggressive malignancy with the potential to metastasize early, 
and there is a pronounced survival difference between localized and metastatic disease 
(Landow et al., 2017; Shaikh et al., 2016; Siegel et al., 2018; Whiteman et al., 2015). 
Despite newly available targeted and immunomodulatory agents for the treatment of 
melanoma (Andtbacka et al., 2015; Clarke et al., 2018; Hodi et al., 2016; Long et al., 2017; 
Ribas et al., 2016; Ribas et al., 2015; Robert et al., 2015; Schachter et al., 2017), the 
durability of the response is not yet known and systemic therapies lead to cures in a 
relatively small number of patients. Therefore, early detection is crucial for favorable 
outcomes, but early definitive diagnosis can be difficult due to the overlap in clinical and 
histopathological appearances of melanomas and highly prevalent melanocytic nevi (moles) 
(Strauss et al., 2007). Histopathological review is the ‘gold standard’ for melanoma 
diagnosis; however, numerous studies have reported interobserver discordance in the 
diagnosis of melanocytic lesions even by expert dermatopathologists (Brochez et al., 2002; 
Elmore et al., 2017; Shoo et al., 2010; Veenhuizen et al., 1997). In one study (Farmer et al., 
1996), review of 40 benign and malignant melanocytic lesions by eight dermatopathologists 
produced discordant diagnoses in 38% of cases. Moreover, certain nevus subtypes, 
especially dysplastic nevi, Spitz nevi, and atypical blue nevi can be difficult to distinguish 
from melanoma (Brochez et al., 2002; Gerami et al., 2014). The difficulty in accurately 
diagnosing melanoma presents a quandary for clinicians, who biopsy and often re-excise 
with margins large numbers of dysplastic nevi in the population (Fung, 2003), due in part to 
lack of confidence in the histopathological diagnosis. A critical need exists for improving 
diagnostic methods to avoid under- and over-treatment of melanocytic lesions. However, the 
small size of melanocytic lesions and early melanomas, which are typically submitted in 
their entirety in formalin to the pathologist for diagnosis, present particular challenges as 
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any new diagnostic test needs to perform reliably on small formalin-fixed paraffin-embedded 
(FFPE) samples.
Prior studies have shown that melanomas differ from nevi at the molecular level, exhibiting 
variations in mRNA expression (Alexandrescu et al., 2010; Clarke et al., 2015; Haqq et al., 
2005; Koh et al., 2009; Talantov et al., 2005), gene copy number (Bastian et al., 2000; 
Bastian et al., 2003; Bauer and Bastian, 2006; Gerami et al., 2009; North et al., 2014; Shain 
et al., 2015), protein expression (Busam, 2013; Ivan and Prieto, 2010; Uguen et al., 2015), 
and DNA methylation (Conway et al., 2011; Gao et al., 2013; Gao et al., 2014), indicating 
that certain molecular biomarkers could provide valuable tools for melanoma diagnosis, 
alone or with histopathology. However, due to the practical limitations of typically small 
FFPE samples and technical challenges or labor intensity in the performance and 
implementation of some assays, few molecular differences have been translated to the clinic 
for melanoma diagnosis.
DNA methylation is a relatively stable epigenetic modification to the DNA that does not 
alter the nucleotide sequence but is associated with variation in gene expression (Plass, 
2002). Changes in methylation at CpG dinucleotides in the upstream regulatory regions of 
genes are often among the earliest events observed during neoplastic progression of 
precancerous lesions (Arai and Kanai, 2010), and hypermethylation of CpG islands in tumor 
suppressor gene promoters is a common mechanism of gene silencing in human cancer 
(Herman and Baylin, 2003). Aberrant DNA methylation occurs widely in melanomas 
(Furuta et al., 2004; Hoon et al., 2004), and we (Conway et al., 2011) and others (Gao et al., 
2013; Gao et al., 2014) have reported differences in DNA methylation between primary 
melanomas and nevi, supporting the use of epigenetic biomarkers for early melanoma 
diagnosis.
Our initial study using a methylation array that targeted cancer-related genes provided proof-
of-principle that DNA methylation differences could distinguish invasive primary 
melanomas from benign nevi in small FFPE samples (Conway et al., 2011; Thomas et al., 
2014). In the present study, we extend this work by identifying and independently validating 
a highly accurate 40-CpG melanoma classifier that distinguishes primary melanomas from a 
broad histopathologic spectrum of nevi within a set of melanocytic samples reviewed by a 
panel of expert dermatopathologists. These findings could translate to a robust melanoma 
diagnostic test ideal for use in FFPE melanocytic samples.
RESULTS
Patient and sample characteristics
Illumina Infinium HumanMethylation450 BeadChip (450K) analysis was successfully 
performed on 97% of samples tested. The clinicopathologic characteristics of the sample set 
are included in Table 1. The sample set of FFPE tissues included 89 cutaneous primary 
invasive melanomas, 73 nevi, and 41 melanocytic proliferations of uncertain malignant 
potential (‘uncertain’ samples). All melanomas and nevi were classified based on complete 
consensus between the original pathology report and three dermatopathology reviewers (four 
interpretations), although we did not exclude a lesion as melanoma if the majority of 
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dermatopathologists interpreted the lesion as melanoma and visceral metastases and/or death 
from melanoma provided unequivocal evidence of the malignancy of the lesion. The 
diagnostically uncertain samples lacked complete consensus between the four interpretations 
or were called uncertain by any dermatopathologist or the pathology report.
The melanomas had median Breslow thickness of 1.85 millimeters (mm) (range of 0.37–
17.00 mm) and were balanced for 7th Edition American Joint Committee on Cancer (AJCC) 
tumor stages (Balch et al., 2009), and both sample classes were comprised of common and 
less common histopathological subtypes. The 73 nevi included intradermal, common 
acquired, dysplastic, Spitz, and blue nevi. The 203 specimens (89 melanomas, 73 nevi, and 
41 uncertain samples) were from 202 different patients; one patient had two synchronous 
primary melanomas, both of which were included in the study. Melanoma patients were 
more frequently older than nevus patients (P < 0.001). Melanomas and nevi (excluding 
uncertain samples) were randomly divided into training (67% of samples; 60 melanomas and 
48 nevi) and validation (33%; 29 melanomas and 25 nevi) sets (Table 1); these did not differ 
significantly in patient age, sex or other clinical or histopathological characteristics.
Development of a 40-CpG melanoma classifier and validation in an independent test set
Monte-Carlo cross validation via ElasticNet was used to develop and compare the diagnostic 
accuracy of CpG classifiers derived from multiple Infinium HumanMethylation450 (450K) 
probe sets in the training set. Inclusion of all CpG probes provided slightly better diagnostic 
accuracy than a limited set of probes associated with candidate genes identified from our 
prior study (Conway et al., 2011) (Supplementary Figures S1a-c online). When accounting 
for age differences in the models by either removing age-associated probes or adjusting for 
age, or both, each method resulted in a prediction model with inferior diagnostic 
discrimination; however, this could be overcome by increasing the number of features in the 
age-adjusted models. Restricting the models to probes showing larger methylation 
differences (β interquartile range [IQR] > 0.2) between melanomas and nevi (Supplementary 
Figures S1a and S1b online) and/or to probes with Illumina gene annotation (Supplementary 
Figure S1d online) produced results very comparable to the more complete probe sets. 
Based on comparative performance of the models, we identified a 40-CpG melanoma 
classifier associated with 38 genes for further characterization derived from the probe set 
filtered for IQR > 0.2 β and with gene annotation (n = 41,448 probes; Supplementary Figure 
S1d online). CpGs contributing to the 40-CpG melanoma classifier were hypermethylated (n 
= 23) or hypomethylated (n = 17) in melanomas relative to nevi. The majority of classifier 
CpGs were located in the upstream regulatory regions of genes (TSS200, TSS1500, 5’UTR), 
including one-third in enhancer regions (Table 2). Neighboring CpGs around the classifier 
probes were also similarly differentially methylated in melanomas (Supplementary Figure 
S2 online).
The heatmap in Figure 1a illustrates the differential methylation at the 40-CpG melanoma 
classifier probes in primary melanomas and nevi with diagnostic consensus in the training 
and validation sets. Separate heatmaps for the training and validation sets are also provided 
in Supplementary Figure S3 online. As shown in Figure 1b, the 40 CpG diagnostic classifier 
distinguishes all histological subtypes of nevi, including dysplastic and Spitz nevi, from 
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melanomas. Moreover, early T1a melanomas or thin melanomas with Breslow thickness 
<1.0 mm were distinguished from nevi (Supplementary Figure S4 online). The diagnostic 
accuracy of the classifier for melanoma in the independent validation set was high (AUC = 
0.996), with a sensitivity of 96.6%, specificity of 100%, positive predictive value (PPV) of 
100.0%, and negative predictive value (NPV) of 96.2% (Figure 1c). Principle components 
analysis (PCA) confirmed the segregation of melanomas from nevi based on the 40-CpG 
melanoma classifier (Figure 1d).
Despite the age difference between melanoma and nevus patients and age-associated CpGs 
being retained in the model, the 40-CpG melanoma classifier performed similarly in 
differentiating melanomas from nevi among both younger (≤ 50 years; AUC = 0.996) and 
older (> 50 years; AUC = 1.00) patients (Supplementary Figure S5 online). The classifier 
was also accurate irrespective of patient sex, tissue source, anatomic site, pigmentation, 
purity of the lesion, or degree of solar elastosis in adjacent skin (Supplementary Table S1 
online). Compared with the dermatopathologist consensus, 2 of 89 samples (2.2%) were 
molecularly reclassified by the 40-CpG classifier; both were melanomas identified as nevi. 
One was a thin superficial spreading melanoma (Breslow thickness = 0.54 mm); the patient 
was alive with no evidence of disease (ANED) 15 months after diagnosis. The other was a 
nodular melanoma (Breslow thickness = 6.86 mm) from a 5-year old child who was ANED 
33 months after diagnosis.
DAVID gene ontology analysis indicated that the 40-CpG melanoma classifier was enriched 
in homeobox genes that play roles in embryonic development and differentiation (e.g., 
PAX3, TLX3, SHOX2, ALX3, SIX6, HOXD12, ONECUT1), other transcriptional 
regulatory genes (HAND2, TBX5, ZBTB38), and genes involved in neurological processes 
(NRXN1, SHANK3, HAND2, MBP, OPCML, SORCS2) (Supplementary Table S2 online).
Validation of the classifier CpGs/genes in independent datasets
Data from published studies were used to confirm diagnostic methylation differences or to 
assess the biological relevance of differentially methylated genes by examining associated 
mRNA expression differences in melanomas versus nevi. As shown in the heatmap and 
associated waterfall plot in Figure 2a, application of the 40-CpG melanoma classifier to 105 
primary melanomas in The Cancer Genome Atlas (TCGA) 450K methylation dataset 
(TCGA, 2015) confirmed 103 of these as melanomas despite TCGA primary melanomas 
being generally of higher tumor stage and obtained as frozen samples compared with 
UNC/UR study samples. Moreover, 367 metastatic melanomas from TCGA showed a 
similar range of classifier scores as the TCGA primary melanomas (Figure 2b). Using 450K 
methylation data from the study of Wouters et al. (Wouters et al., 2017), primary and 
metastatic melanomas were accurately distinguished from nevi with AUC of 1.000 (Figures 
2c and 2d). Using 27K methylation data from the study of Gao and colleagues (Gao et al., 
2013), PCA of methylation at 44 CpGs associated with genes in the 40-CpG diagnostic 
classifier distinguished primary melanomas from nevi (Figure 2e); only two of these probes 
directly overlapped probes in the 40-CpG classifier (cg03874199 in HOXD12; cg19352038 
in PAX3) and these exhibited large differences in methylation between melanomas and nevi 
(Figure 2f). Differential mRNA expression of several diagnostic genes, including PAX3, 
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TBX5, MBP, GOLIM4, and ANKH, also differentiated primary melanomas from nevi in the 
dataset of Talantov et al (Talantov et al., 2005) (Supplementary Figure S6 online).
40-CpG melanoma classifier calls in uncertain samples
The 40-CpG classifier may be most clinically useful as an aid in the diagnosis of ambiguous 
melanocytic samples lacking agreement between dermatopathologists. Therefore, it was of 
interest to apply the 40-CpG melanoma classifier to the 41 diagnostically uncertain samples. 
The supervised heatmap in Figure 3a illustrates methylation levels at the 40 diagnostic CpGs 
in uncertain samples along with the melanomas and nevi having diagnostic consensus, 
ordered from lowest (negative for nevi) to highest classifier score (positive for melanoma). 
In total, 36 uncertain samples were called nevus and 5 were called melanoma by the 
classifier, as shown in the waterfall plot (Figure 3b). These results, together with the 
boxplots in Figure 3c summarizing classifier scores for the three diagnostic categories, show 
that the uncertain samples reside mainly among the nevi or between the nevi and primary 
invasive melanomas. This is further confirmed by PCA based on either the 40 classifier 
CpGs (Figure 3d) or the larger probe set (n=41,448) from which the classifier was derived 
(Supplementary Figure S7 online). The placement by the classifier of many diagnostically 
uncertain samples among the nevi is generally consistent with the pathology reviews in 
which 30 of 41 were called either nevus or uncertain by all the dermatopathology reviewers, 
while only 11 were called melanoma by any dermatopathology reviewer (Supplementary 
Table S8 online).
DISCUSSION
This study identified a 40-CpG melanoma classifier that distinguished cutaneous primary 
invasive melanomas, including thin melanomas, from nevi with a sensitivity of 96.6% and 
specificity of 100.0% in the validation set. Methylation analysis was successfully performed 
on >97% of FFPE samples. The classifier is comprised of a combination of CpGs exhibiting 
hypermethylation (n = 23) or hypomethylation (n = 17) in melanomas relative to nevi. 
Although melanoma patients are typically older than those being biopsied for nevi, as in this 
dataset, the diagnostic accuracy of the classifier was similarly very high among both 
younger and older patients. Importantly, the classifier confirmed as melanoma nearly all 472 
primary and metastatic melanomas in TCGA and was further independently validated in 
published methylation and gene expression datasets. Application of the classifier to 
uncertain samples predicted many to be nevi and a few to be melanomas. Thus, we believe 
the identification of a diagnostically uncertain melanocytic specimen as melanoma by the 
classifier increases the probability that it is a melanoma. As expected, some classifier scores 
for uncertain samples fell near the interface of melanoma and nevus, suggesting they may be 
in transition toward melanoma, and future work will focus on the characterization of such 
samples.
The 40 classifier CpGs for melanoma are associated with 38 genes heavily enriched for 
homeobox developmental transcription factors (ALX3, HOXD12, ONECUT1, PAX3, 
SHOX2, SIX6, TLX3) and other transcriptional regulators (TBX5, ZBTB38, MYT1L). 
PAX3, a marker of melanocytic cells, is a key regulator of melanocyte development and has 
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putative roles in cell survival, migration, and differentiation (Dye et al., 2013; Medic and 
Ziman, 2009; 2010). Altered methylation of PAX3 and several other melanoma classifier 
genes (HOXD12, OPCML, GIMAP7, FAIM3) has previously been reported in melanomas 
versus nevi (Conway et al., 2011; Furuta et al., 2004; Gao et al., 2013; Jin et al., 2015). 
PROM1 (CD133), a stem cell marker involved in maintaining stem cell pluripotency, is 
frequently expressed in melanomas (Sharma et al., 2010; Zimmerer et al., 2016). Gene 
ontology analysis revealed associations of several diagnostic genes with neural tissues/
processes (e.g., OPCML, NRXN1, HAND2, MYT1L, MBP, TLX3), reflecting their 
common embryologic derivation with melanocytes from neural crest cells (Noisa and 
Raivio, 2014). FLJ22536, recently identified as CASC15, is a putative mediator of neural 
growth and differentiation and a tumor suppressor in neuroblastoma (Russell et al., 2015), 
and in melanoma is linked to disease progression and phenotype switching between 
proliferative and invasive states (Lessard et al., 2015). Other diagnostic genes lack well-
defined roles in melanoma; however, in other cancer types, a number exhibit aberrant 
expression (Gao et al., 2015; Jiang et al., 2008; Makiyama et al., 2005) and/or methylation 
(Jones et al., 2013; Kikuchi et al., 2013; Lai et al., 2008; Li et al., 2015; Semaan et al., 2016; 
Song et al., 2015; Wimmer et al., 2002; Yu et al., 2010; Zhao et al., 2013), function in 
apoptosis (Baras et al., 2009; Baras et al., 2011; Causeret et al., 2016) or differentiation (Zha 
et al., 2012), or are diagnostic (Semaan et al., 2016; Song et al., 2015; Xing et al., 2015), 
prognostic (Dietrich et al., 2013; Galluzzi et al., 2013; Qiu et al., 2015; Zheng et al., 2015; 
Zhou et al., 2014) or predictive biomarkers (Tada et al., 2011).
Our 40-CpG classifier for melanoma diagnosis may have advantages over other available 
approaches for melanoma diagnosis. In current clinical pathology practice, immunostains 
(e.g., Ki67, HMB45, p16) can aid pathologists’ interpretation of melanocytic lesions, but 
single stains have low diagnostic accuracy (Uguen et al., 2015); combination staining may 
have higher accuracy but requires pathologist interpretation and lacks independent 
validation. Copy number analyses by comparative genomic hybridization (CGH) show that 
most melanomas, but few nevi, harbor numerous chromosomal changes (Bastian et al., 
2000; Bauer and Bastian, 2006); however, CGH requires more tissue than is typically 
available from melanocytic samples. Fluorescence in situ hybridization detection of specific 
chromosomal changes is viewed directly on slides, using little tissue, but unlike CGH 
examines a limited number of chromosomes and requires technical expertise for 
interpretation (Busam, 2013). These currently utilized tests suffer from unclear diagnostic 
accuracy across the broad spectrum of melanoma and nevus subtypes (Ivan and Prieto, 
2010) and limited independent validation. The Myriad MyPath Melanoma mRNA 
expression-based test showed reasonably high diagnostic accuracy (sensitivity and 
specificity >90%) for melanoma, but has a failure rate as high as 25% in FFPE archival 
samples (versus < 3% in this study) (Clarke et al., 2015; Ko et al., 2017). The 40-CpG 
melanoma classifier is an approach that combines high accuracy across diverse melanocytic 
subtypes, technical robustness, and the ability to reliably screen early, small melanomas.
A strength of this study is that the 40-CpG melanoma classifier was developed from a 
genome-wide methylation platform allowing unbiased selection of loci. Notably, some of the 
identified loci may function in the neoplastic transition toward melanoma. Further, we 
utilized melanomas with a wide range of different AJCC tumor stages, including thin T1a 
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melanomas, and diverse subtypes of both melanomas and nevi, such as dysplastic nevi, 
considered to be potential precursor lesions. For classification of melanoma or nevus in the 
training and validation sets, we required complete diagnostic consensus among three expert 
dermatopathologists and the original pathology report, crucial for achieving a highly 
accurate diagnostic classifier. Moreover, the classifier probes include only those with larger 
methylation differences between melanomas and nevi, which allows more reliable detection 
of these differences. Since the classifier was developed using FFPE samples similar to those 
typically found in clinical practice and requires amounts of DNA that can be recovered from 
most melanocytic samples, we expect the technology can be translated to clinical practice. 
Limitations of the study are its retrospective nature with potential sample selection bias. 
Another limitation is the absence of long-term follow-up of all patients.
In summary, our diagnostic 40-CpG melanoma classifier showed high accuracy in the 
validation set comprised of varied melanoma and nevus subtypes and was independently 
validated in public sample sets. Due to the robust nature of the assay, the 40-CpG melanoma 
classifier should be reliable on typical clinical samples. The assay also may have some 
advantages over other technologies due to its high diagnostic accuracy, need for less DNA, 
and robust methodology. However, additional studies are needed to further validate the 
performance of the classifier and optimize classifier score thresholds among larger numbers 




FFPE primary melanomas, nevi, and uncertain samples were assembled from the pathology 
archives of the University of North Carolina (UNC) Hospitals or from the University of 
Rochester (UR) Medical Center based on original diagnoses abstracted from pathology 
reports and diagnosed between 2001 and 2012. The Institutional Review Boards at UNC and 
the UR approved the study. Melanomas were chosen to span AJCC tumor stages and 
included common and less common subtypes (e.g., Spitzoid, nevoid, and desmoplastic 
melanomas). Nevi were chosen to include intradermal melanocytic nevi, including those 
with congenital pattern, compound melanocytic nevi with mild to severe dysplasia, Spitz and 
blue nevi, and other uncommon nevi (e.g. deep penetrating nevus, pigmented spindle cell 
nevus, and proliferative nodule in congenital pattern nevus). In addition, melanocytic 
proliferations of uncertain malignant potential were selected. Age, sex, race, and anatomic 
site were abstracted from the medical chart. Histopathological review of all samples was 
conducted independently by three expert dermatopathologists to assign diagnoses of 
melanoma or nevus or to identify uncertain samples. One dermatopathologist conducted a 
centralized histopathological review for histopathological pigment and adjacent solar 
elastosis of all the melanocytic lesions, for the histopathological subtype of nevi, and for 
histopathological subtype, Breslow thickness, mitoses, ulceration, and tumor infiltrating 
lymphocytes of the melanomas. Details of the histopathology are provided in Table 1. 
Details on the interobserver review are provided in the Supplementary Methods online. The 
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IRB determined the research met criteria for waiver of informed consent for research [45 
CFR 46.116(d)] and waiver of HIPAA authorization [45 CFR 164.512(i)(2)(ii)].
DNA preparation and bisulfite treatment
Melanocytic lesions were manually microdissected using H&E slides as guides, and DNA 
was prepared as described (Thomas et al., 2004; Thomas et al., 2007). Sodium bisulfite 
modification of 250–300 ng DNA from each FFPE tissue was performed using the EZ DNA 
Methylation Lightning kit (Zymo Research, Orange, CA) according to the manufacturer’s 
protocol.
Infinium HumanMethylation450 BeadChip analysis
Bisulfite-modified DNA (120 ng) was processed through the Illumina Infinium HD FFPE 
Restore protocol according to the manufacturer’s instructions, and Illumina Infinium 
HumanMethylation450 BeadChip (450K) array analysis was performed in the Mammalian 
Genotyping Core at UNC. Details on methylation array analysis and data preprocessing are 
provided in the Supplementary Methods online. The final dataset contained 383,229 probes 
and 203 samples (89 melanomas, 73 nevi, 41 uncertain, and 12 controls). Methylation data 
were deposited to Gene Expression Omnibus under accession number GSE120878.
Statistical analyses
To develop a diagnostic classifier distinguishing melanomas from nevi, melanomas and nevi 
with diagnostic consensus were split into training (67% of each sample class) and validation 
(the remaining 33%) sets. Multiple predictive models based on different probe sets were 
tested for their ability to distinguish melanomas from nevi; these included accounting for 
effects of age and limiting probes to the most differentially methylated. For each probe set, 
Monte-Carlo cross validation with 100 iterations was performed on training samples using 
the ElasticNet algorithm implemented in R package glmnet (Zou and Hastie, 2005) to obtain 
optimal parameters (alpha and the number of probes) that best differentiate melanomas. In 
each iteration, 2/3 of the training set was randomly selected to build the elastic model and to 
predict on the rest of the 1/3 in the training set. Based on the average AUC across 100 
iterations, we determined the number of probes to be included in the final model. Classifier 
scores were calculated using the β value of selected probes in the final model. Heatmaps 
were generated to illustrate methylation at the diagnostic probe set, and PCA was performed 
to illustrate the segregation of melanomas and nevi. Additional details of model 
development and validation are provided in the Supplementary Methods online.
Independent validation in published methylation datasets
Illumina 450K methylation data for TCGA melanomas were downloaded from the Broad 
Institute Firehose web portal (http://firebrowse.org/) (version 2016012800). Illumina 450K 
methylation data for melanomas and nevi from the study of Wouters et al (Wouters et al., 
2017) were obtained from Gene Expression Omnibus (GEO) (accession number 
GSE86355). Illumina Infinium HumanMethylation27 (27K) methylation data for 
melanomas and nevi were downloaded from GEO (accession number GSE45266) from the 
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study of Gao et al (Gao et al., 2013). Details of independent validation are provided in the 
Supplementary Methods online.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations:
AUC area under the curve
FFPE formalin-fixed, paraffin-embedded
IQR interquartile range
NPV negative predictive value
PA promoter-associated
PCA principal component analysis
PPV positive predictive value
ROC receiver operating characteristic
TCGA The Cancer Genome Atlas
TSS transcription start site
UCTS unclassified cell type-specific
UNC University of North Carolina
uncl unclassified
UR University of Rochester
UTR untranslated region
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Figure 1. Performance of the 40-CpG melanoma classifier in training and/or validation sets.
Specimens in the training (60 melanomas and 48 nevi) and validation (29 melanomas and 25 
nevi) sets had diagnostic consensus on interobserver review. The 40 diagnostic probes were 
identified from the model that analyzed annotated probes with IQR > 0.2 β between 
melanomas and nevi. (a) Heatmap showing methylation at 40 classifier probes in melanomas 
(red) and nevi (blue) from the combined training (white) and validation sets (green). Red 
represents highly methylated and blue represents unmethylated. (b) Boxplots of classifier 
scores for histological subtypes of nevi and melanomas. (c) ROC plot showing diagnostic 
accuracy in the validation set. (d) PCA showing the segregation of melanoma and nevus 
samples based on the 40 CpG classifier.
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Figure 2. Independent validation of differential methylation at classifier CpG loci.
Validation of the diagnostic classifier was conducted in three public datasets. (a) 40-CpG 
methylation heatmap and waterfall plot of classifier scores in 105 primary melanomas from 
TCGA (TCGA, 2015) (yellow) compared with 89 melanomas and 73 nevi from UNC/UR 
(green). (b) Boxplots showing classifier scores for TCGA primary or metastatic melanomas 
and UNC/UR primary melanomas and nevi. (c) Boxplots showing classifier scores for 33 
primary and 28 metastatic melanomas, and 14 nevi, and (d) ROC plot showing the 
diagnostic accuracy of the 40 CpG classifier comparing nevi to primary melanomas in the 
GSE86355 450K methylation dataset. In the GSE45266 27K methylation dataset, (e) PCA 
of methylation at 44 CpGs associated with diagnostic classifier genes illustrates segregation 
of 24 primary melanomas from 5 nevi, and (f) boxplots showing methylation differences at 
the 2 CpG loci (cg3874199 and cg19352038) directly matching 450K probes in the 
diagnostic classifier.
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Figure 3. Diagnostic 40-CpG melanoma classifier calls on melanomas, nevi, and diagnostically 
uncertain samples.
Interobserver dermatopathologic review identified 89 melanomas, 73 nevi, and 41 uncertain 
samples. (a) Supervised heatmap, ordered left to right from lowest to highest diagnostic 
classifier score, showing methylation levels at the 40 diagnostic CpGs in melanomas (red) or 
nevi (blue) from the training (white) or validation sets (green), or uncertain samples (gray). 
(b) Waterfall plot of classifier scores, ordered as in the heatmap, and color-coded for 
diagnosis. (c) Boxplots of classifier scores for each diagnostic category, with median and 
interquartile range encompassed by each box. The broken lines indicate the classifier score 
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threshold for distinguishing melanomas from nevi. (d) PCA plot shows sample segregation 
based on the 40 CpG classifier.
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